

June 21, 2018

Company name: RIBOMIC Inc.
Representative: Yoshikazu Nakamura, President and CEO
Stock code: 4591
Listing: Tokyo Stock Exchange, Mothers Market
Contact: Emiko Nakamura, Corporate Officer,
Corporate Planning Department

**Notice of Completion of IND submission of RBM-007 for Treatment of
Age-related Macular Degeneration**

We are pleased to inform that RIBOMIC USA Inc., a wholly owned subsidiary of RIBOMIC Inc., submitted Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the treatment of wet Age-related Macular Degeneration (AMD) using RBM-007, a novel oligonucleotide-based aptamer having potent anti- Fibroblast Growth Factor 2 (FGF2) activity.

AMD is an age-related disorder that affects the macula of the retina. It is the leading cause of blindness in the United States and Europe. All of FDA-approved therapies for AMD act against the same target, Vascular Endothelial Growth Factor (VEGF), which is a major contributor to the pathogenesis of wet AMD. Although treatments with anti-VEGF drugs have shown dramatic visual benefits for AMD patients, follow-up studies have revealed some limitations. First, the efficacy of anti VEGF drugs is poor in a certain number of patients. Second, even with patients who showed dramatic visual acuity improvement at first step of the treatment, long-term visual outcomes are poor. These factors are thought to involve scarring (fibrosis) of the retinal tissue, but existing drugs do not suppress scarring. In contrast, pharmacological studies of RBM-007 in disease model animals have shown that RBM-007 inhibits not only angiogenesis but also scar formation. These dual effects are novel mechanisms that may provide new therapies for wet AMD patients. The substance patent of RBM-007 is already granted in the United States.

As soon as the IND becomes effective, RIBOMIC will initiate Phase I/IIa trial (named as SUSHI study) in the United States. The main purpose of the SUSHI study is to investigate the safety and acceptability of RBM-007 Injectable Solution. It is planned to be conducted in small number of patients at several clinical trial sites in the United States. Thereafter we plan to proceed to Phase IIb trial (named as TOFU study) to determine mainly the efficacy of RBM-007.